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Although dengue (DEN) virus is the etiologic agent of dengue fever, the most prevalent vector-borne viral disease in the
world, precise information on the antigenic structure of the dengue virion is limited. We have prepared a set of murine
monoclonal antibodies (MAbs) specific for the envelope (E) glycoprotein of DEN 2 virus and used these antibodies in a
comprehensive biological and biochemical analysis to identify 16 epitopes. Following domain nomenclature developed for the
related flavivirus, tick-borne encephalitis, three functional domains were identified. Five epitopes associated with domain A
were arranged in three spatially independent regions. These A-domain epitopes were destroyed by reduction, and antibodies
reactive with these epitopes were able to block virus hemagglutination, neutralize virus infectivity, and block virus-mediated
cell membrane fusion. Domain-A epitopes were present on the full-length E glycoprotein, a 45-kDa tryptic peptide repre-
senting its first 400 amino acids (aa) and a 22-kDa tryptic peptide representing at least aa 1–120. Four epitopes mapped into
domain B, as determined by their partial resistance to reduction and the localization of these epitopes on a 9-kDa tryptic or
chymotryptic peptide fragment (aa 300–400). One domain-B-reactive MAb was also capable of binding to a DEN 2 synthetic
peptide corresponding to aa 333–351 of the E glycoprotein, confirming the location of this domain. Domain-B epitopes elicited
MAbs that were potent neutralizers of virus infectivity and blocked hemagglutination, but they did not block virus-mediated
cell-membrane fusion. Domains A and B were spatially associated. As with tick-borne encephalitis virus, determination of
domain C was more problematic; however, at least four epitopes had biochemical characteristics consistent with C-domain
epitopes.
INTRODUCTION
While dengue continues to be the most important
arthropod-borne flaviviral disease, and many immune
reagents, including monoclonal antibodies (MAbs) and
antipeptide antibodies, have been prepared against
these viruses, our understanding of the antigenic struc-
ture and intermolecular interactions of the dengue (DEN)
virus surface glycoproteins lags behind that of another
flavivirus, tick-borne encephalitis (TBE) virus. Studies
with TBE virus have led to good understanding of some
of the structure/function relationships of the virion struc-
tural proteins, especially the major flavivirus envelope
(E)-glycoprotein (Mandl et al., 1989; for review see Heinz
and Roehrig, 1990; Roehrig, 1997).
Using MAb analysis, researchers have identified three
antigenic domains (A, B, and C) on the E-glycoprotein of
TBE virus (Guirakhoo et al., 1989). The A domain [approx-
imately amino acids (aa) 50–130 and 185–300] was iden-
tified as a linearly discontinuous domain, separated by a
C domain (approximately aa 130–185). The A-domain
structure is stabilized by five disulfide bridges and, there-
fore, contains epitopes susceptible to reduction, many of
which elicit virus-neutralizing antibodies. Functional A-
domain epitopes as measured by MAb binding are found
only on the intact E glycoprotein or on a 45-kDa tryptic
fragment approximately composed of aa 1–380. Much of
the antigenicity of the B domain requires a disulfide bond
between Cys 11 and Cys 12, is far more conformationally
stable, and is identifiable as a trypsin/chymotrypsin-re-
sistant core of 9 kDa (approximately aa 300–400)(Winkler
et al., 1987). Epitopes located in the B domain can elicit
virus-neutralizing or hemagglutination-inhibiting MAbs.
The TBE C domain is conformationally stable; however,
many C-domain epitopes are lost following proteolytic
digestion. Only one of six C-domain epitopes elicited a
MAb with virus-neutralizing activity.
Recently, the 2 Å molecular structure of the amino-
terminal 45-kDa tryptic fragment of the TBE E glycop-
rotein homodimer was solved (Rey et al., 1995). The E
glycoprotein folds into three distinct domains (I, II, and
III), which correlate well to the previously defined
domains C, A, and B. Because the locations of the
E-glycoprotein Cys residues are conserved among all
flaviviruses, it is generally assumed that this overall
structure is the same for all flaviviruses, including DEN
virus. It must be noted, however, that similar studies
with DEN virus or other flaviviruses have not been
done, so extrapolation of results from TBE virus stud-
ies to all other flaviviruses needs to be experimentally
confirmed.
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A variety of antigenic mapping experiments have
been performed with DEN viruses by using expressed
recombinant fragments to further define the epitopes
on the DEN virus E glycoprotein (Innis et al., 1989;
Aaskov et al., 1989; Mason et al., 1989; Megret et al.,
1992; Trirawatanapong et al., 1992; Lin et al., 1994;
Hiramatsu et al., 1996). Using a panel of synthetic
peptides derived from the deduced amino acid se-
quence of the E glycoprotein of DEN-2 Jamaica (JAM)
virus, which included most of its 495 aa, we deter-
mined previously that 11 peptides defined four anti-
genic regions (aa 1–55; 79–172; 225–249; and 333–
388) that could elicit antiviral antibody reactive in an
enzyme-linked immunosorbent assay (ELISA), in which
virus was absorbed to the ELISA plate (Roehrig et al.,
1990, 1994). These regions could be mapped to do-
mains A (aa 1–55; 79–142; 225–249), C (aa 79–172),
and B(aa 333–388). Two peptides (aa 35–55 and 352–
368) elicited low levels of virus-neutralizing antibody in
mice. One observation of particular interest was the
ability of some of these antipeptides to react better
with virus that had been exposed to low pH. These
peptides were localized in two linearly discontinuous
regions, aa 58–120 and 225–249. One of these regions
contained the putative flavivirus fusion sequence (aa
98–110) that is presumably exposed by treatment of
the E glycoprotein with acid. A subsequent study
linked mutations in the E glycoprotein aa 6, 134, and
153 with alterations in virus-mediated cell-membrane
fusion (Guirakhoo et al., 1993).
A limited MAb map for DEN-2 virus has been devel-
oped (Gentry et al., 1982; Henchal et al., 1985; Monath
et al., 1986; Jianmin et al., 1995). Seven E-glycoprotein
epitopes were identified on the DEN-2, New Guinea C
(NGC) strain by Henchal et al. (1985). In this study,
epitopes arranged themselves in a spatial continuum
when analyzed by antibody competitive binding assay
(CBA). One MAb that mapped an epitope not in this
spatial continuum was shown to be reactive with the
prM protein. Results from subsequent studies gener-
ally confirmed these results with very few exceptions
(Monath et al., 1986; Jianmin et al., 1995). One notable
difference was the identified spatial relationship of the
epitopes defined by MAbs 3H5 and 4E5. While these
studies identified epitopes of the DEN 2 virus E gly-
coprotein, they did not investigate the structure–func-
tion properties and relationships of this protein in the
same detail as has been done with the TBE virus. To
document the antigenic structure of the DEN virus E
glycoprotein, we now report the isolation and charac-
terization of a set of DEN 2 virus-elicited IgG MAbs.
We have used these MAbs to map more precisely the
biologically important epitopes and domains on the
DEN-2 virus E glycoprotein. Not unexpectedly, our
results are very similar to those determined for TBE
virus. This expanded understanding of the DEN-2 virus
E-glycoprotein structure and the availability of these
well-characterized anti-DEN MAbs should be most
useful in DEN virus vaccine design.
RESULTS
MAb characterization and epitope identification
Ten individual fusions were performed, by using mice
immunized with high-pH virus alone, with low-pH virus
alone, or with a combination of low-pH virus followed by
high-pH virus. Combining the MAbs developed here with
the previously characterized MAbs, we identified 16 in-
dependent epitopes on the DEN 2 virus E glycoprotein
(Table 1). The epitopes were identified by a combination
of chemical and serological tests. We were also able to
identify one MAb that was specific for the DEN 2 virus
nucleocapsid protein, MAb 1A2A-1. This MAb and the
previously prepared MAb reactive with the prM protein
(MAb, 2H2) served as excellent control antibodies in
the various serological assays. Three of our MAbs
defined epitopes with serologic activities and chemi-
cal stabilities with three Mabs previously described
by Henchal et al. (1985): 9A3D-8 (similar to 3H5),
1A1D-2 (9D12), and 6B6C-1 (4G2). None of the 16 E-gly-
coprotein epitopes were more accessible on low-pH-
treated virus when compared to high-pH virus when
either plate-bound or antibody-captured viruses were
used in ELISA (data not shown). The serologic specificity
of these 16 MAbs ranged from DEN 2 virus specific to
flavivirus group reactive (Table 1). The MAb 4E5 reacted
with DEN 1, 2, and 3 viruses in these ELISA assays. This
observed 4E5 cross-reactivity was different than that
previously reported by Henchal et al. (1985), but con-
firmed later 4E5 cross-reactivity reported by Kaufman et
al. (1987).
Conformational requirements for epitope activity
To determine the conformational requirements of
these epitopes, virus–antibody reactivity was determined
by using immunoblotting with and without reduction with
2-mercaptoethanol (Table 1). Three reactivity patterns
were identified: partial resistance to 2-mercaptoethanol
(1A6A-8, 9A3D-8, 1A1D-2, 10A4D-2, and 10A1D-2); sensi-
tivity to 2-mercaptoethanol (2B3A-1, 1A5D-1, 2H3, 1B4C-2,
4A2B-4, 4E5, 13B7, 1B7 and 6B6C-1); and sensitivity to
SDS denaturation (4A5C-8 and 9A4D-1).
Virus neutralization epitopes
MAbs that neutralized infectivity define epitopes
that could be either somewhat conformationally stable
(9A3D-8, 1A1D-2, and 10A4D-2) or conformationally
dependent (4E5, 1B7, and 6B6C-1) (Table 1). Not sur-
prisingly, most MAbs that neutralized virus infectivity
(MAbs 9A3D-8, 1A1D-2, 10A4D-2, 1B7, and 6B6C-1)
bound well to epitopes that were accessible on the
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surface of the native virion, as determined in the an-
tigen-capture ELISA. Two MAbs (2H3 and 1A5D-1) had
intermediate binding to captured virus and had no
(1A5D-1) or low (2H3) neutralizing activity. One MAb,
4E5, could neutralize virus infectivity without recogniz-
ing native virus. The reactivity patterns of these MAbs
in the indirect or antigen-capture ELISA with another
DEN 2 virus, NGC, were identical to that with DEN 2,
JAM (data not shown).
HI and blocking DEN virus-mediated cell fusion
Seven MAbs—9A3D-8, 1A1D-2, 3H5, 2H3, 4E5, 1B7,
and 6B6C-1—were capable of blocking hemagglutina-
tion of red blood cells by either purified DEN 2 virus or
DEN virus-infected SMB. The ability of the previously
defined MAbs to block HA of SMB DEN antigen is in-
cluded in Table 1 for comparison (Henchal et al., 1985).
Three MAbs—4E5, 1B7, and 6B6C-1—were capable of
blocking DEN virus-mediated cell fusion (Table 1).
Spatial arrangement of epitopes based on CBA
CBA analysis was performed to localize epitopes de-
fined by these MAbs. Two of the 16 MAbs (4A2B-4 and
10A1D-2) were not of high enough binding affinity for
CBA analysis, and MAb 13B7 was not in sufficient quan-
tity to include in the CBA. MAb 1A6A-8 only had high
affinity for completely reduced antigen and was therefore
useless in CBA on nonreduced virus. Thirteen MAbs
included in the CBA defined three spatially distinct do-
mains (Fig. 1); 10 epitopes clustered into a single spatial
domain. Figure 2 compares the chemical and biological
characteristics of each epitope within its spatial config-
uration. From these data, an epitope map was derived,
based on the TBE nomenclature (Fig. 3).
TABLE 1
Serological, Biological, and Biochemical Characteristics of DEN 2 E Glycoprotein Epitopes Defined by Monoclonal Antibodies
MAba Agb Isotype
Immunoblotc PRNTd
Capture
ELISA Indirect ELISA reactivitye HIf
Fusion
inhibition
2ME 1ME (.90%) (DEN2) DEN1 DEN2 DEN3 DEN4 SLE Virus SMB (C6/36)
E glycoprotein
9A4D-1g L/H IgG2A O ND 2 2.9 ,3.0 4.4 ,3.0 ,3.0 ,3.0 ,1.0 ,1.0 ,2.0
1A6A-8 High IgG2A E E 2 2.3 ,3.0 5.0 ,3.0 ,3.0 ,3.0 ,1.0 ,1.0 ,2.0
4A5C-8g Low IgG2B O ND 2 2.0 ,3.0 3.2 ,3.0 ,3.0 ,3.0 ,1.0 ,1.0 ,2.0
2B3A-1 Low IgG2A E O 2 2.0 ,3.0 5.3 ,3.0 ,3.0 ,3.0 ,1.0 ,1.0 ,2.0
9A3D-8 L/H IgG2A E E 1 .5.3 ,3.0 .5.3 ,3.0 ,3.0 ,3.0 1.9 ,1.0 ,2.0
1A5D-1 High IgG2A E O 2 3.5 ,3.0 .5.3 ,3.0 ,3.0 ,3.0 ,1.0 ,1.0 ,2.0
2H3 SMB IgG2A,1 E O 6 3.8 ,4.0 4.6 ,4.0 ,4.0 ,3.0 ND 1 ,2.0
IB4C-2 High IgG2A E O 2 .5.3 ,3.0 .5.3 5.7 ,3.0 ,3.0 ,1.0 ,1.0 ,2.0
4A2B-4 Low IgG2b E O 2 2.0 ,3.0 3.0 ,3.0 3.6 ,3.0 ,1.0 ,1.0 ,2.0
1A1D-2 High IgG2A E E 1 .5.3 5.1 .5.3 5.4 ,3.0 ,3.0 1.6 ,1.0 ,2.0
4E5 SMB IgG2A,1 E O 1 2.6 3.8 4.2 3.2 ,2.0 ,3.0 ND 1 3.0
1OA4D-2 L/H IgG2A E E 1 5.3 3.9 .5.3 3.9 3.0 ,3.0 ,1.0 ,1.0 ,2.0
13B7 SMB IgG2A E O 2 2.3 5.2 4.6 4.3 ,3.0 ,3.0 ND ND ND
1OA1D-2 L/H IgG2A E E 2 2.9 3.6 4.4 3.6 3.3 3.6 ,1.0 ,1.0 ,2.0
1B7 SMB IgG2A E O 1 .5.3 4.3 4.9 4.6 4.6 4.5 ND 1 3.2
6B6C-1 SLE IgG2A E O 6 .5.3 4.6 5.2 4.9 4.9 5.1 2.5 2.2 2.6
prM protein
2H2 SMB IgG2A prM O 2 2.3 4.6 4.6 4.9 4.3 ,3.0 ND 2 ,2.0
Capsid
protein
1A2A-1 High IgG2B C C 2 2.0 ,3.0 4.1 ,3.0 ,3.0 ,3.0 #10 #10 ,2.0
Note. Fusion, virus-mediated cell-membrane fusion; SLE, St. Louis encephalitis; IgG, immunoglobulin G.
a Monoclonal antibodies analyzed.
b Antigen used for mouse immunizations: High, normal virus; low, virus treated at pH 5.0; L/H, 1° inoculation low-pH virus, 2° inoculation normal
virus; SMB, suckling mouse brain antigen.
c Protein specificities: E, envelope glycoprotein; prM, precursor to M protein; C, capsid protein; O, no reactivity detected; ND, not determined.
d Plaque reduction neutralization activity at 1:100 dilution of ascitic fluid.
e Reciprocal end point ELISA titers, log10.
f Reciprocal end point hemagglutination inhibition tiers, log10, using purified virus or SMB antigen. A ‘‘1’’ or ‘‘2’’ denotes previously reported results
(Henchal et al., 1985). ND denotes not determined.
g These MAbs were also tested by radioimmunoprecipitation assay. The MAb 4A5C-8 precipitated the E glycoprotein in both the presence and the
absence of sodium dodecyl sulfate. The MAb 9A4D-1 did not precipitate the E glycoprotein in the radioimmunoprecipitation assay in either the
presence or the absence of sodium dodecyl sulfate.
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Peptide mapping of the E glycoprotein
To further localize epitopes, purified virus was di-
gested with either TPCK–trypsin or a-chymotrypsin.
The resultant peptide fragments were separated by
SDS–PAGE with or without 2-mercaptoethanol, and
reactivity with either MAbs or anti-peptide antibodies
was measured by immunoblotting. Only MAb 1A6A-8
reacted with reduced peptide fragments (data not
shown). Six tryptic fragments of the E glycoprotein (45,
30, 28 (triplet), 25, 22, and 9 kDa) could be readily
identified (Fig. 4A, lane 10) and could be localized
based on their reactivity with defined antipeptide an-
tibodies (Figs. 4A and 4B). Two other bands were
apparent in these profiles: prM (20 kDa) and capsid (12
kDa). These proteins were not digested under the
proteolytic conditions used here. The intact E glyco-
protein (50-kDa band) and the 45-kDa fragment re-
acted with all antipeptides (Fig. 4A, lanes 11 to 16). The
45-kDa fragment most probably corresponds to the
45-kDa TBE tryptic fragment approximately containing
aa 1–400 (Fig. 4A, lanes 11 to 16). This was the frag-
ment used to solve the three-dimensional structure of
the TBE E glycoprotein.
The 30-, 28-, and 25-kDa fragments were reactive
with antipeptides elicited by aa 142–368 (Fig. 4A, lanes
14 to 16), but not antipeptides elicited by aa 35–140
(Fig. 4A, lanes 11 and 13). Based on this antipeptide
reactivity pattern, predicted tryptic cleavages sites,
and peptide molecular mass, the most likely location
of these fragments would be within aa 158–400. The
22-kDa fragment reacted weakly with antipeptides
elicited by aa 35–105 (Fig 4A, lanes 11 and 12); there-
fore, the most likely location of this fragment would be
within at least aa 1–120. The 9-kDa fragment that
resulted from digestion with either trypsin or chymo-
trypsin appears to be identical to the 9-kDa tryptic
fragment observed with TBE virus. The location of this
fragment would be aa 300–400, which is consistent
with its reactivity only with the antipeptide 17 (aa
352–368)(Figs. 4A, lane 16, and 4B, lane 3).
Localization of MAb binding site on peptide
fragments
Comparing binding of MAbs to either tryptic or chy-
motryptic peptide fragments revealed at least three
binding patterns (Fig. 5). Similar to the CBA results,
MAbs 1A1D-2, 10A4D-2, and 9A3D-8 bound the same
tryptic fragments: the 45, 30, 28, 25, and 9-kDa pep-
tides (Fig 4A, lanes 1 to 3). These MAbs also bound
the same chymotryptic fragments (Fig. 4B, lanes 1 and
2). This binding pattern suggests that the epitopes for
these MAbs are located on the 9-kDa fragment which
is in turn included within the 45, 30, 28, and 25-kDa
peptides (Fig. 5). The second binding pattern was
observed for MAbs 10A1D-2 (Figs. 4A, lane 4, and 4B,
lane 4) and 6B6C-1 (Fig. 4A, lane 5) and 1B7 (Fig. 4A,
lane 6) and was unusual: besides binding to the E
glycoprotein and the 45- and 30-kDa fragments, they
were the only MAbs to recognize 22-kDa tryptic or
chymotryptic fragments (Fig. 5). These MAbs did not
bind the 9-kDa fragment, indicating that their defined
epitopes were not located within aa 300–400 (Fig. 5).
The third binding pattern was represented by Mabs
2H3 and 1B4C-2 (data not shown) which bound only to
the E glycoprotein or the large 45-kDa fragment (Figs.
4A, lane 7 for 2H3, and 5).
MAb binding to synthetic peptides
The binding of these MAbs to 25 synthetic peptides,
which included most of the 495 aa of the DEN 2 virus E
glycoprotein, was analyzed by indirect ELISA (Roehrig
et al., 1994). A screening assay was first performed
that used the MAbs at 1:1000 dilutions. The binding of
FIG. 1. Competitive binding assay map of DEN 2 E-glycoprotein epitopes. Circles indicate independent epitopes defined by noted MAb. Overlapping
circles indicate competition.
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each MAb to peptide 470 (aa 470–493, part of the E-gly-
coprotein hydrophobic tail and not immunogenic) was
used as background binding, and absorbance values
twofold higher than this were considered positive. Posi-
tive MAb reactions in the screening assay were then
titrated to end point. Only one MAb, 10A4D-2, demon-
strated significant binding to any peptide (16, aa 333–
351). The reciprocal log10 end point titer of this peptide
binding activity (4.2) was comparable to its virus binding
activity (5.3).
DISCUSSION
The results of this study have permitted us to identify
and to arrange the DEN 2 E-glycoprotein epitopes in a
manner similar to that of TBE virus. The sensitivity to
reduction–denaturation of epitopes defined by MAbs
1A5D-1, 6B6C-1, 4E5, 2H3, and 1B7 was consistent with
E-glycoprotein A-domain epitopes. Located within do-
main A is the putative flavivirus membrane fusion se-
quence (aa 98–110). It is this fusion sequence that is
FIG. 2. Summary of the chemical and biological activities of identified E-glycoprotein epitopes as derived from Table 1. For surface accessibility,
antigen-capture log10 ELISA titers were interpreted as low (2.0–3.0), medium (3.0–5.0), and high ($5.0).
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presumed to become more accessible at low pH. Virus-
mediated cell-membrane fusion can be blocked by three
of these MAbs, 4E5, 1B7, and 6B6C-1. While MAbs
1A5D-1, 6B6C-1, 1B7, and 2H3 readily recognize native
virus, the MAb 4E5 can neutralize virus infectivity, but did
not bind to intact virus. The only defined mechanism of
flavivirus neutralization to date is inhibition of virus-me-
diated cell-membrane fusion (Gollins and and Porterfield,
1986). It is reasonable to hypothesize that MAb 4E5
effects virus neutralization through this previously de-
fined mechanism and binds to native virus only after it
has undergone a low-pH-catalyzed conformational
change.
Using antipeptide antibodies, we previously identified
two A-domain regions of the E glycoprotein that were
made more accessible to antibody binding following
virus treatment with low pH. These regions, aa 58–120
(peptides 3-8/1; 3-8/2; and 4-6) and 225–249 (peptide 6),
are discontinuous in the primary structure of the E gly-
coprotein. When the three-dimensional structure of the
TBE virus E glycoprotein is analyzed, it can be shown
that these discontinuous regions are actually spatially
related (Fig. 6). The three-dimensional structure of the
TBE glycoprotein homodimer also indicates that the two
amino acids associated with virus-mediated cell-mem-
brane fusion (aa 6 and 153, Guirakhoo et al., 1993) and
the other area capable of eliciting low-level virus-neu-
tralizing antibody (peptide 35) create a pocket for the
putative fusion sequence (aa 98–110) of the alternate
monomer (Fig. 6), as was first hypothesized by Rey et al.,
1995. It has been suggested that the N-linked carbohy-
drate acceptor motif at DEN virus aa 153 (aa 154 in TBE
FIG. 3. Epitope assignments of the DEN 2 E glycoprotein. Epitope assignments to domain A (white), domain B (shaded), and domain C
(cross-hatched). Squares indicate hemagglutination inhibition activity (filled squares, hemagglutination inhibition positive) and circles indicate
neutralization (N) activity (filled circles, N positive). Also listed are domains I, II, and III as defined by X-ray crystallography.
FIG. 4. Antibody reactivities with proteolytic fragments of DEN 2 virus. Immunoblot reactivity of MAbs and antipeptide antibodies with nonreduced
tryptic (A) or chymotryptic (B) peptides of DEN 2 virus. Position of molecular mass standards (right of); virion structural proteins (E, prM, C); and peptide
fragments are shown. (A) Lanes 1, 1A1D-2; 2, 10A4D-2; 3, 9A3D-8; 4, 10A1D-2; 5, 6B6C-1; 6, 1B7; 7, 2H3; 8, 1A2A-1 (anti-capsid); 9, 1F1 (DEN 1 specific
negative control); 10, Gold-blot total protein stain; 11, antipeptide 35 (aa 35–55); 12, antipeptide 4-6 (aa 72–105); 13, antipeptide 4 (aa 121–140); 14,
antipeptide 142 (aa 142–172); 15, antipeptide 6 (aa 225–249); 16, antipeptide 17 (aa 352–368). (B) Lanes 1, 9A3D-8; 2, 10A4D-2; 3, antipeptide 17; 4,
10A1D-2; 4, anti-capsid 1A2A-1.
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virus) when utilized functions to stabilize the fusion do-
main and inhibit its release during virion maturation (Rey
et al., 1995). The DEN 2 virus aa 153 N-linked glycosyl-
ation site is not used, however (Johnson et al., 1994).
Instead, the DEN 2 virus glycoprotein is glycosylated at
aa 67, which is not spatially related to the fusion domain
(Fig. 6). The significance of this change has yet to be
defined; however, it calls into question the necessity of
glycosylation at aa 153 for proper maintenance of a
functional E glycoprotein in DEN 2 virus.
Localization of three of the A-domain epitopes defined
by MAbs 6B6C-1, 10A1D-2, and 1B7 was confirmed by
the reactivity of these MAbs with the 22-kDa tryptic and
chymotryptic peptide (aa 1–120). These MAbs were also
somewhat reactive, however, with the 30-kDa tryptic
peptide (aa 158–400; Fig. 4A, lanes 4–6). These results
seem to indicate that the epitopes defined by MAbs
6B6C-1, 10A1D-2, and 1B7 might be composed of discon-
tinuous parts of the E glycoprotein aa backbone. While
this observation seems unusual, a similar result for the
epitope defined by MAb 1B7 has been previously re-
ported (Aaskov et al., 1989). Using pepscan analysis,
these investigators concluded that the 1B7-defined
epitope was composed of aa 50–57 and 127–134 (do-
main A) and 349–356 (domain B). Investigating the three-
dimensional structure of the E glycoprotein reveals that
indeed the 22- and 30-kDa peptides are spatially close
(Fig. 5). The weak reactivity of antipeptides 35 and 4-6
with the 22-kDa fragment makes unambiguous localiza-
tion of this fragment difficult. It is clear, however that
MAbs and antipeptides recognizing the remainder of the
protein fail to bind to this 22-kDa fragment, which indi-
cates that it is not included in a.a. 158–400. It is possible
that the secondary structure maintained in the nonre-
duced gel that is necessary for MAb binding inhibits
antipeptide binding which is most efficient with reduced
peptides.
The biochemical characteristics of the epitopes de-
fined by MAbs 9A3D-8, 10A4D-2, 3H5, and 1A1D-2 are
consistent with location in B domain, based on their
partial resistance to reduction–denaturation, their reac-
tivity with the 9-kDa tryptic fragment (aa 300–400), and
the binding of MAb 10A4D-2 to peptide 16 (aa 333–351,
Fig. 6). These MAbs have potent virus-neutralizing activ-
ity. Using a combination of both Escherichia coli expres-
sion and synthetic peptides, Trirawatanapong et al.
(1992) mapped the MAb 3H5 binding site to aa 386–397.
A peptide derived from this region elicited low-level vi-
rus-neutralizing antibody in rabbits (titers of 1:10 to 1:80
at 80% plaque reduction end points). In our hands a very
similar peptide (aa 388–400) could not bind to MAb 3H5
nor elicit virus-neutralizing antibody in mice (Roehrig et
al., 1990). A more recent study using site-directed mu-
tagenesis of a DEN 2/DEN 4 chimeric virus derived from
an infectious cDNA clone identified the E-P-G at aa
383–385 as being critical for MAb 3H5 binding (Hira-
matsu et al., 1996). These investigators concluded that
aa 383–385 most probably defined the MAb 3H5 binding
site. The P-384 residue was clearly the most critical aa in
this triad, with viruses mutant at aa 384 losing all reac-
tivity with 3H5 in three different serologic assays. Proline
residues introduce b-turns in the polypeptide, so it is
still uncertain whether this loss of 3H5 reactivity with aa
384 mutants is the result of the inability of 3H5 to bind aa
384 or the inability of 3H5 to bind a proximal sequence
with altered presentation by the substitution of the P at
aa 384.
Two other lines of experimental evidence support our
definition of the domains of DEN 2 virus. In a previous
FIG. 5. Localization of MAb reactivity on peptide fragments. Using
the defined X-ray diffraction crystal prediction for the tick-borne en-
cephalitis virus E glycoprotein, the location of the observed tryptic
peptides (space-filling balls) within the 45-kDa protein backbone (line)
is identified. The MAbs reactive with each fragment is listed to the right.
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study, we observed that one of two DEN peptides able to
elicit virus-neutralizing antibody was located in the B
domain (peptide 17, aa 352–368, Fig. 6). This peptide is
adjacent to the binding site of MAb 10A4D-2 (peptide 16,
Fig. 6). Our CBA results do not link the epitope defined by
3H5 (B domain) with that of 4E5 (A domain). These
results support the epitope map first developed by Hen-
chal et al. (1985).
Megret et al. (1992) identified six antigenic domains
using trp–E-glycoprotein fusion proteins from DEN 2 Ja-
maica virus. Multiple epitopes were identified by virus-
neutralizing MAbs. One B-domain region fragment (aa
298–397) reacted with type-, subcomplex-, complex-,
subgroup-, and group-reactive MAbs. Two A-domain
fragments (aa 60–135 and 60–205) defined a group-re-
active epitope. These domains were also similar to those
identified previously by using either pin-bound or free
peptides (Aaskov et al., 1989; Roehrig et al., 1990, 1994).
It has been hypothesized that the mechanism of neu-
tralization of B-domain antibodies is blocking attachment
of the virus to the cell receptor. The evidence for this is
indirect; however, it is based upon the observation that
MAb neutralization escape variants, whose mutations
are located in the B domain, have altered biological
characteristics (Mandl et al., 1989). The virion anti-recep-
tor still remains to be defined. Except for MAb 4E5, all
virus-neutralizing MAbs were able to bind to native virus,
indicating that these epitopes in both domains A and B
were accessible on the virion surface.
Because of the lack of biological activity associated
with the C domain (aa 130–185), assignment of this
domain is more problematic. The characteristics of four
epitopes closely linked in CBA defined by MAbs 4A5C-8,
1B4C-2, 2B3A-1, and 9A4D-1 are most consistent with the
C domain. Two of these MAbs (4A5C-8 and 9A4D-1)
define the only two epitopes that are susceptible to
simple denaturation by anionic detergents. None of
these C-domain MAbs has measurable biological activity
(HI, N, or blocking fusion). Results with Murray Valley
encephalitis virus suggest that the C domain may be the
molecular hinge for the acid-catalyzed release of the
fusion domain of the E glycoprotein (Guirakhoo et al.,
1992).
Because of limitations of antibody avidity or quantity,
the location of epitopes defined by four of these MAbs
could not be precisely determined. Earlier investigations
that used an alternative CBA format localized the epitope
defined by MAb 13B7 with other epitopes in the B domain
(Henchal et al., 1985). The biochemical characteristics
determined here of the epitope defined by MAb 13B7 are
more compatible with the A domain. MAb 1A6A-8 de-
fined an epitope that was most reactive on reduced and
denatured virus. This was the only epitope with these
characteristics and probably explains the inability of
MAb 1A6A-8 to react well in the CBA, which uses non-
reduced virus. While the binding avidity of either MAbs
4A2B-4 or 10A1D-2 was too low to make them useful in
CBA, the biochemical characteristics of the epitope de-
fined by these MAbs makes their location in A domain
likely. This conclusion is also supported by the binding
pattern of 10A1D-2 with tryptic or chymotryptic frag-
ments, where its binding profile is similar to that of 1B7
and 6B6C-1 (Fig. 4B, lane 4). Because of these limita-
tions, epitopes defined by MAbs 13B7, 1A6A-8, 4A2B-4,
and 10A1D-2 could not be included in our CBA map.
The results of this study indicate that while the DEN
virus E glycoprotein assumes antigenic characteristics
similar to those of TBE virus, subtle differences do occur.
This well-defined panel of DEN 2 virus-derived MAbs will
allow us to define more precisely the interactions of the
DEN virus surface proteins and not require extrapolation
of results derived with TBE virus. These MAbs will also
be useful in precisely analyzing the antigenic structure of
future DEN virus vaccine candidates.
MATERIALS AND METHODS
Virus and cells
The virus used to elicit MAbs in this study was DEN 2,
JAM strain 1409. Other strains of DEN viruses used in the
ELISA were DEN 1, Hawaii; DEN 2, NGC; DEN 3, H-241;
and DEN 4, Dominica. The viruses grown in C6/36 cells
and purified on glycerol tartrate gradients (Obijeski et al.,
1974) were used as antigens in subsequent serologic
assays.
Antibody production and characterization
To assess the effects of low pH treatment of virus on
antigenic conformation, male BALB/c mice were immu-
nized for MAb production by using three different inoc-
ulation protocols. All inoculations were composed of 50
mg of a particular virus preparation emulsified in
Freund’s complete adjuvant. Mice were inoculated at
days 0 and 16. The first inoculation protocol used purified
DEN-2 virus that had been maintained at pH $7.5 during
growth and purification (high-pH virus). The antigen used
in the second immunization protocol was high-pH virus
that had been denatured by treatment at pH 5.0 (low-pH
virus). The final immunization protocol used low-pH virus
inoculation followed by high-pH virus inoculation. The
protocol for hybridoma production has been previously
described (Roehrig et al., 1980). Immunized mice were
bled and tested for antiviral antibody in ELISA 20 days
after the second inoculation (Roehrig et al., 1990). Anti-
body-positive mice were boosted one final time, and
spleens were harvested 4 days later and used to prepare
hybridomas. Hybridomas surviving selection with hypox-
anthine–aminopterin–thymidine media were screened by
ELISA for reactivity with both high-pH and low-pH vi-
ruses. Positive hybridomas were cloned two times in soft
agar. High-titered MAbs were prepared as ascitic fluids
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from BALB/c mice. MAbs were isotyped by using an
ELISA-based isotyping kit for murine antibodies accord-
ing to the manufacturer’s recommendations (Amersham
Corp., Arlington Heights, IL.). To make this study as
inclusive as possible, anti-DEN virus MAbs that have
been previously reported were obtained from Dr. Eric
Henchal, United States Army Research Institute of Infec-
tious Diseases. These MAbs—3H5; 2H3; 9D12; 4E5;
13B7; 1B7; 2H2; and 4G2—were prepared from mice
immunized with suckling mouse brain (SMB) antigen of
DEN 2 virus, NGC strain (Gentry et al., 1982; Henchal et
al., 1985). The MAb 6B6C-1 is a flavivirus group-reactive
MAb specific for the E glycoprotein, prepared against St.
Louis encephalitis virus, and defines an epitope with
similar activity as the epitope defined by MAb 4G2 (Roe-
hrig et al., 1983).
Antibody purification
MAbs were purified by high-performance liquid chro-
matography (HPLC) on a 5-mm, 7.75 3 100 mm Baker-
bond AbxVersa-ten column, on a Beckman System Gold
HPLC (Ross et al., 1987). Prior to HPLC, MAb containing
ascitic fluids were diluted 1:3 with 25 mM MES [2(N-
morpholino)ethanesulfonic acid] buffer, pH 6.5 (Buffer A),
and were clarified by centrifugation for 30 min at 39,000
rpm in a Sorvall 641 rotor followed by successive filtra-
tion through 0.45- and 0.2-mm filters. The column was
equilibrated with Buffer A, and 4 ml of clarified ascites
was loaded. Antibody was removed with a 0–25% 1 M
sodium acetate buffer, pH 7.0, over 30 min at a flow rate
of 0.8 ml/min. Protein elution was monitored by absor-
bance at 280 nm, and 1-ml fractions were collected. Peak
fractions were pooled and concentrated into phosphate-
buffered saline (PBS) using a Centricon-10 microconcen-
trator (Amicon, Beverly, MA). Protein concentrations were
determined by using the Bio-Rad protein assay (Bio-Rad
Laboratories, Richmond, Calif.).
Epitope chemical stability analysis
The protein specificities of the isolated MAbs and the
characterizations of the chemical requirement for
epitope expression were done by using either reduced
or nonreduced immunoblotting, or radioimmunoprecipi-
tation (RIP). The procedures have been published previ-
ously. For immunoblotting, purified virus was dissociated
in Laemmli sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) loading buffer with or with-
out 2-mercaptoethanol (Laemmli et al., 1970; Roehrig et
al., 1985). After separation of proteins by SDS-PAGE on
12.5% gels, proteins were blotted onto polyvinylidene
difluoride-Immobilon membranes (Millipore Corp., Bed-
ford, MA) in a Pharmacia Transblotter (Pharmacia, Upp-
sala, Sweden). Membranes were blocked with 3% goat
serum in PBS overnight and were probed for reactivity by
using MAb or polyclonal antibodies. Bound antibodies
were detected with goat anti-mouse antibody conjugated
to alkaline phosphatase (Jackson ImmunoResearch,
West Grove, PA) and blots were developed by using
BCIP/NBT substrate (Kirkegaard & Perry Laboratories,
Inc., Gaithersburg, MD). Total membrane-bound pro-
tein was visualized by staining nonblocked membrane
with Gold-blot protein stain reagent following the manu-
facturer’s instructions (Integrated Separation Systems,
Natick, MA).
MAbs that failed to bind antigen in an immunoblot
were further analyzed by RIP by using previously pub-
lished protocols (Roehrig et al., 1980). Virus used in the
RIP assay was radioactively labeled with [35S]methionine
(Amersham Corp.). The detergent used in this RIP assay
was 1% Triton X-100. Antigen–antibody complexes were
precipitated by using goat anti-mouse antibody coupled
to Sepharose. Bound viral proteins were visualized by
SDS–PAGE on 12.5% gels and autoradiography.
Serological assays
The serological reactivities of these MAbs were tested
in plaque reduction neutralization (PRNT) assays, hem-
agglutination inhibition (HI) assays using either DEN 2
virus SMB antigen or purified DEN 2 high-pH virus, and
two forms of ELISA. The first ELISA format was the
standard indirect ELISA that used purified high- or
low-pH virus adsorbed to Immulon II microtiter plates
(Dynatech Industries, Inc., McLean, VA) (Roehrig et al.,
1980). The second ELISA format was an antigen-capture
ELISA in which DEN 2 virus from tissue culture seed was
captured to plates via a polyclonal rabbit anti-DEN 2
virus antibody, which was a gift from Charles H. Calisher.
This ELISA format was used to detect epitope expres-
sion on the native virion that had not been disrupted by
adsorption to polystyrene. After the antigen was coated
in this way, the ELISA was completed by using the
standard indirect ELISA format. The procedures for PRNT
and HI assays have been previously published (Roehrig
et al., 1983). The PRNT was performed with a 1:100
dilution of ascitic fluid, and a 90% PRNT cutoff was used
to maximize test stringency.
Competitive binding assays
The procedure for antibody CBA mapping of the spa-
tial relationships of epitopes was a modification of our
previously published techniques (Roehrig et al., 1982). In
this assay, we used biotinylated antibodies in place of
enzyme-conjugated antibodies. Purified MAbs were bio-
tinylated by using the Pierce NHS-LC-Biotin Kit, following
the manufacturer’s recommendations (Pierce Biochemi-
cals, Rockford, IL). The CBA assays were performed with
purified virus antigen. Antibody competitors were usually
HPLC purified; however, two competing MAbs were used
as NH2SO4 precipitates (4A2B-4 and 1A1D-2) and four
were unpurified ascitic fluids (9A4D-1, 1A6A-8, 4A5C-8,
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and 10A4D-2). Both competitor and biotinylated antibod-
ies were added at the same time; therefore, promotion of
antibody binding was not observed. Bound biotinylated
antibody was detected by the addition of avidin–peroxi-
dase for 1 h at RT followed by 3,39,5,59-tetramethylben-
zidine substrate (Kirkegaarde & Perry).
Peptide mapping
The procedures for proteolytic cleavage and peptide
mapping were similar to those that have been previously
published (Guirakhoo et al., 1992). For tryptic digestion,
300 mg of purified DEN 2 virus was digested with 10 mg
L-1-p-tosylamino-2-phenylethyl chloromethyl ketone
(TPCK)–trypsin on ice for 30 min. For chymotryptic diges-
tion, 200 mg of purified DEN 2 virus was digested with 10
mg chymotrypsin at 37°C for 30 min. Digestion optimiza-
tion assays indicated that the only virion protein digested
under these conditions was the E glycoprotein (data not
shown). Proteolytic digests were first analyzed by SDS–
PAGE on 15% gels and then probed for antibody reactivity
by immunoblotting. Most MAb reactivity was lost when
peptides were reduced with 2-mercaptoethanol prior to
immunoblotting; therefore, only immunoblots of nonre-
duced peptide mixtures are reported. The preparation
and characterization of antipeptide antibodies used to
identify the peptide fragment location within the glycop-
rotein has been published previously (Roehrig et al.,
1990, 1994).
Antibody blocking of DEN virus-mediated cell
membrane fusion
An assay to measure virus-mediated cell membrane
fusion was performed essentially as previously de-
scribed (Guirakhoo et al., 1992). To effect fusion, DEN 2
virus-infected C6/36 cells were exposed to pH 5.0 at 7
days postinfection. To test the ability of MAbs to block
fusion, virus-infected C6/36 cells in 24-well tissue culture
plates were pretreated for 1 h at 37°C with dilutions of
various MAbs prior to low pH exposure. After MAb treat-
ment, cells were exposed to pH 5.0 as before. Cells were
monitored for syncitia formation. Virus-infected, non-
MAb-treated cells and uninfected MAb-treated cells
were included as controls. The MAb 1H10, which is
specific for the E glycoprotein of DEN 4 virus, was in-
cluded as a negative MAb control.
Molecular modeling of the E glycoprotein
The X-ray crystallographic structure of the E-glycopro-
tein homodimer of TBE virus was accessed from the
Brookhaven protein data base, file 1svb.pdb. Dengue
data were input by using the program RasMol, Ver 2.6,
available from the RasMol homepage, http://www.u-
mass.edu/microbio/rasmol/, at the University of Massa-
chusetts.
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